EA201690633A1 - Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела - Google Patents
Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антителаInfo
- Publication number
- EA201690633A1 EA201690633A1 EA201690633A EA201690633A EA201690633A1 EA 201690633 A1 EA201690633 A1 EA 201690633A1 EA 201690633 A EA201690633 A EA 201690633A EA 201690633 A EA201690633 A EA 201690633A EA 201690633 A1 EA201690633 A1 EA 201690633A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- ctla
- antibodies
- combination
- compositions including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Abstract
Изобретение относится к фармацевтическим композициям, содержащим антагонист VEGF и анти-CTLA-4 антитело, а также способам их применения. Композиции и способы по настоящему изобретению могут быть использованы для лечения разных форм рака и других заболеваний и нарушений, при которых антиангиогенные препараты и/или направленные иммунные ответы могут быть полезны.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361892601P | 2013-10-18 | 2013-10-18 | |
US201361901596P | 2013-11-08 | 2013-11-08 | |
US201461952923P | 2014-03-14 | 2014-03-14 | |
US201462055734P | 2014-09-26 | 2014-09-26 | |
PCT/US2014/061071 WO2015058048A1 (en) | 2013-10-18 | 2014-10-17 | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201690633A1 true EA201690633A1 (ru) | 2016-08-31 |
EA037890B1 EA037890B1 (ru) | 2021-06-01 |
Family
ID=51844874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201690633A EA037890B1 (ru) | 2013-10-18 | 2014-10-17 | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела |
Country Status (11)
Country | Link |
---|---|
US (2) | US9968674B2 (ru) |
EP (1) | EP3057990B1 (ru) |
JP (1) | JP6607850B2 (ru) |
KR (1) | KR102338453B1 (ru) |
CN (1) | CN105636986B (ru) |
AU (1) | AU2014337135B2 (ru) |
CA (1) | CA2926853C (ru) |
EA (1) | EA037890B1 (ru) |
IL (1) | IL244599B (ru) |
MX (1) | MX2016004736A (ru) |
WO (1) | WO2015058048A1 (ru) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
CA2942776C (en) | 2014-03-17 | 2023-01-24 | Adverum Biotechnologies, Inc. | Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
KR20170137730A (ko) | 2015-03-02 | 2017-12-13 | 애드베룸 바이오테크놀로지스, 인코포레이티드 | 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법 |
DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
KR20180104635A (ko) | 2015-12-30 | 2018-09-21 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
WO2017165778A1 (en) | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
RS61311B1 (sr) * | 2016-06-16 | 2021-02-26 | Adverum Biotechnologies Inc | Lečenje amd korišćenjem varijante aav2 sa afliberceptom |
CA3030298A1 (en) | 2016-07-20 | 2018-01-25 | Aerpio Therapeutics, Inc. | Humanized monoclonal antibodies that target ve-ptp (hptp-.beta.) |
EA201991383A1 (ru) | 2016-12-07 | 2019-12-30 | Эйдженус Инк. | Антитела против ctla-4 и способы их применения |
WO2018144587A1 (en) * | 2017-01-31 | 2018-08-09 | Research Development Foundation | Steap2 inhibitors for the treatment of liver cancers |
US20210040212A1 (en) * | 2018-02-02 | 2021-02-11 | Oncolmmune, Inc. | Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects |
EP3746479A4 (en) * | 2018-02-02 | 2021-11-24 | OncoC4, Inc. | MUTANT ANTI-CTLA -4 ANTIBODIES WITH IMPROVED IMMUNOTHERAPEUTIC EFFECT BUT MITIGATED SIDE EFFECTS |
US20210047410A1 (en) * | 2018-02-02 | 2021-02-18 | Oncolmmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
JP2021514656A (ja) * | 2018-03-02 | 2021-06-17 | コディアック サイエンシーズ インコーポレイテッドKodiak Sciences Inc. | Il−6抗体ならびにその融合構築物およびコンジュゲート |
WO2020068653A1 (en) | 2018-09-24 | 2020-04-02 | Aerpio Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF |
EP3873940A4 (en) | 2018-10-31 | 2022-11-30 | BioAtla, Inc. | ANTI-CTLA4 ANTIBODIES, ANTIBODY FRAGMENTS, THEIR IMMUNOCONJUGATES AND USES THEREOF |
CN111378044B (zh) * | 2018-12-28 | 2022-07-15 | 长春金赛药业有限责任公司 | 抗体融合蛋白、制备方法及其应用 |
JP2022523063A (ja) * | 2019-01-30 | 2022-04-21 | アムジエン・インコーポレーテツド | アフリベルセプトの属性、並びにその特性決定及び修飾方法 |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19802753A1 (de) | 1998-01-26 | 1999-07-29 | Merck Patent Gmbh | Coreaktive Trägermaterialien zur Heterogenisierung von Katalysatoren, Cokatalysatoren und Liganden |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US7303746B2 (en) * | 1999-06-08 | 2007-12-04 | Regeneron Pharmaceuticals, Inc. | Methods of treating eye disorders with modified chimeric polypeptides |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
CA2586844A1 (en) * | 2004-11-04 | 2006-05-11 | Pfizer Products Inc. | Ctla-4 antibody and aromatase inhibitor or combination treatment for breast cancer |
CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
EP2212432A4 (en) * | 2007-10-22 | 2011-10-19 | Schering Corp | COMPLETELY HUMAN ANTI-VEGF ANTIBODIES AND USE PROCEDURES |
US8263073B2 (en) | 2008-02-04 | 2012-09-11 | Medarex, Inc. | Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
-
2014
- 2014-10-17 EP EP14792686.9A patent/EP3057990B1/en active Active
- 2014-10-17 WO PCT/US2014/061071 patent/WO2015058048A1/en active Application Filing
- 2014-10-17 MX MX2016004736A patent/MX2016004736A/es active IP Right Grant
- 2014-10-17 US US15/026,460 patent/US9968674B2/en active Active
- 2014-10-17 EA EA201690633A patent/EA037890B1/ru unknown
- 2014-10-17 JP JP2016524116A patent/JP6607850B2/ja active Active
- 2014-10-17 KR KR1020167013164A patent/KR102338453B1/ko active IP Right Grant
- 2014-10-17 AU AU2014337135A patent/AU2014337135B2/en active Active
- 2014-10-17 CN CN201480054902.1A patent/CN105636986B/zh active Active
- 2014-10-17 CA CA2926853A patent/CA2926853C/en active Active
-
2016
- 2016-03-15 IL IL24459916A patent/IL244599B/en active IP Right Grant
-
2018
- 2018-04-23 US US15/959,595 patent/US10532096B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2926853C (en) | 2022-04-26 |
CN105636986A (zh) | 2016-06-01 |
EP3057990A1 (en) | 2016-08-24 |
IL244599B (en) | 2019-10-31 |
US10532096B2 (en) | 2020-01-14 |
IL244599A0 (en) | 2016-04-21 |
US20160243225A1 (en) | 2016-08-25 |
KR102338453B1 (ko) | 2021-12-13 |
AU2014337135B2 (en) | 2019-09-19 |
US20180236070A1 (en) | 2018-08-23 |
WO2015058048A1 (en) | 2015-04-23 |
EP3057990B1 (en) | 2019-09-04 |
KR20160067978A (ko) | 2016-06-14 |
JP2016539096A (ja) | 2016-12-15 |
JP6607850B2 (ja) | 2019-11-20 |
MX2016004736A (es) | 2016-07-26 |
EA037890B1 (ru) | 2021-06-01 |
US9968674B2 (en) | 2018-05-15 |
CN105636986B (zh) | 2020-05-12 |
CA2926853A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201690633A1 (ru) | Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
EA201891186A1 (ru) | Антитела, нейтрализующие вирус иммунодефицита человека | |
EA201790932A1 (ru) | Дозировка и введение нефукозилированных анти-cd40 антител | |
EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
EA201791093A1 (ru) | Антитела к cd47, способы и применение | |
EA201692458A1 (ru) | Анти-gitr антитела и способы их применения | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201890530A1 (ru) | Конъюгаты антитела к dll3 и лекарственного средства и способы их применения | |
EA201691582A1 (ru) | Новые фармацевтические препараты | |
EA201591166A1 (ru) | Ингибиторы аутотаксина | |
EA201690881A1 (ru) | Соединения-ингибиторы аутотаксина | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201591616A1 (ru) | Трифторметил-замещенные аннелированные пиримидины и их применение | |
EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
EA201590388A1 (ru) | Способы лечения таупатии | |
EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201591801A1 (ru) | Лекарственные конъюгаты антител | |
EA201790334A1 (ru) | Конъюгаты анти-cdh6 антитела с лекарственным средством | |
EA201391416A1 (ru) | Новые соединения в качестве модуляторов протеинкиназ | |
EA201591611A1 (ru) | Конъюгаты антитело-лекарственное средство | |
EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида |